Recordati stock: Equita targets EUR 69.00 for Recordati stock

Published on 10/19/2026 at 16:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due November 10, 2026. Recordati stock costs EUR 52.98 on October 19, 2026 at 4:01 p.m. CEST, down 0.04 percent versus the Xetra close.

Equita frames the next report

On October 14, 2026, Equita recommended a EUR 69.00 target for Recordati.
Barron's lists November 10, 2026 for Recordati's third-quarter results.
Recordati stock costs EUR 52.98 at Lang & Schwarz on October 19, 2026 at 4:01 p.m. CEST, 0.04 percent below the Xetra close of October 16, 2026.
Recordati had EUR 10.8 billion market value and a P/E ratio of 22.25 on October 16, 2026.

Pop-Art-Comic-Illustration eines Wissenschaftlers, der eine große Kapsel hochhält — Recordati S.p.A. (IT0003828271) wird als Pharma-Unternehmen durch diese farbenfrohe Pop-Art-Comic-Illustration mit Wissenschaftler dargestellt, Illustration mit AI erstellt.

On October 14, 2026, Equita recommended a EUR 69.00 target for Recordati, placing the target 30.24 percent above the EUR 52.98 price at Lang & Schwarz. The assessment was reported by Il Sole 24 ORE.

Recordati's next reported milestone is the third-quarter results date. Barron's lists November 10, 2026 for the release, giving investors a defined calendar point for the next operating update.

Stock stays below yearly high

Recordati's 52-week range was EUR 43.76 to EUR 54.45 as of October 16, 2026. At EUR 52.98, the stock stood 2.70 percent below that high. Lang & Schwarz quoted a EUR 52.95 bid and a EUR 53.00 ask at 4:01 p.m. CEST on October 19, 2026. The finance quote for the Milan listing showed 101,693 shares traded against an average volume of 340,868 shares.

Valuation and November date

Recordati carried a market capitalization of EUR 10.8 billion and a trailing P/E ratio of 22.25 as of October 16, 2026. Its year-to-date performance was 9.09 percent, while the dividend yield was 2.53 percent. The November 10 reporting date matters because the company last posted first-half 2026 results on July 29, 2026, according to Recordati's investor calendar.

Comparison with peers on October 19, 2026

Recordati: minus 0.04 percent, P/E 22.25, market capitalization EUR 10.8 billion.

Sanofi (Euronext Paris, EUR): minus 0.92 percent, P/E 22.00, market capitalization EUR 85.4 billion.

Ipsen (Euronext Paris, EUR): minus 0.40 percent, P/E 23.95, market capitalization EUR 12.3 billion.

Price remains near the yearly high

The narrow gap to Recordati's 52-week high leaves the stock close to its upper trading boundary, while the Equita target provides a separate valuation reference. Recordati was trading at EUR 52.98 at Lang & Schwarz on October 19, 2026 at 4:01 p.m. CEST, 0.04 percent below the Xetra close of October 16, 2026. The further course of trading is shown by the continuously updated real-time quote of Recordati stock.